Actively Recruiting
Safety and Feasibility Study of CARCIK CD12333 Cell Therapy for Relapsed or Refractory AML and BPDCN in Children and Adults
Led by Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Updated on 2026-10-16
18
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and feasibility of CARCIK-CD12333 cell infusion in adults and children with relapsed or refractory acute myeloid leukemia AML and blastic plasmacytoid dendritic cell neoplasm BPDCN. This phase III clinical trial focuses on patients who have exhausted conventional treatment options and are candidates for allogeneic hematopoietic cell transplantation alloHCT. Participants receive a split dose of CARCIK CD12333 cells, a non-viral allogeneic dual chimeric antigen receptor therapy targeting CD123 and CD33. The study involves a single group of patients treated with this experimental cell infusion, conducted prior to a planned alloHCT. The treatment aims to assess safety and therapeutic feasibility in both pediatric and adult populations. During the study, participants undergo evaluations including tumor assessments in bone marrow and peripheral blood by morphology and flow cytometry. Researchers monitor long-term survival up to 12 months after treatment. Safety assessments, organ function tests, pregnancy tests for females of childbearing potential, and performance status evaluations are performed. Participants may also be monitored for the presence of CAR positive viable T cells by quantitative PCR. Study participation duration spans from treatment through follow-up to assess outcomes and safety.
CONDITIONS
Brief Title
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here